Cell Therapeutics, Inc., a biopharmaceutical company, engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. The company is developing Pixuvri, a novel anthracycline derivative for the treatment of non-Hodgkins lymphoma, as well as for various other hematologic malignancies and solid tumors; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, brain, esophageal, and non-small cell lung cancer; and Brostallicin, a phase II trial for the treatment of metastatic triple-negative breast cancer. It is also developing Bisplatinates, a platinum-based chemotherapy drug to treat various kinds of cancers. The company has collaboration and licensing agreements with PG-TXL Company, L.P.; Gynecologic Oncology Group; Nerviano Medical Sciences; Cephalon; and Novartis. Cell Therapeutics, Inc. was founded in 1991 and is based in Seattle, Washington.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.

All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: Publisher@StockGuru.com or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070